FHA
SMMT icon

First Horizon Advisors’s Summit Therapeutics SMMT Stock Holding History

First Horizon Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$16.7K Buy
+785
New +$17.9K ﹤0.01% 1491

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

First Horizon Advisors's SMMT Position: Q2 2025 in Review

First Horizon Advisors opened a new position in Summit Therapeutics (SMMT) in Q2 2025: 785 shares worth $16.7K. The stake represents ﹤0.01% of the portfolio and ranks #1491 among its holdings.

238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • First Horizon Advisors held 785 shares of Summit Therapeutics worth $16.7K as of Q2 2025.
  • Summit Therapeutics was a new First Horizon Advisors position in Q2 2025.
  • Summit Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1491 holding.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.